| Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study
|
| Author(s): "Kerstin M G Brand, Laura Saarelainen, Jaak Sonajalg, Emmanuelle Boutmy, Caroline Foch, Marja Vääräsmäki, Laure Morin-Papunen, Judith Schlachter, CLUE Study Group, Katja M Hakkarainen, Pasi Korhonen
CLUE Study Group: Minna Vehkala, Robyn Thorén, Henrik Svanström "
|
| Affiliations(s): "Leading author: Kerstin Brand: Merck KGaA, Darmstadt, Germany
IQVIA author affiliations: Global Database Studies, IQVIA, Espoo, Finland; Global Database Studies, IQVIA, Tartu, Estonia; Global Database Studies, IQVIA, Solna, Sweden; Global Database Studies, IQVIA"
|
Publication(s): BMJ Open Diab Res Care 2022;10:e002363. doi:10.1136/bmjdrc-2021-002363
|
| Document Type(s): Article, |
| Countries: Finland, |
| Click here for the abstract |
C:
Y: |
Diabetes, Obesity,
2022 |
|
L:
A: |
English
Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective cohort analysis, |
|
 |
| |
| |
| A novel decision model to predict the impact of weight management interventions: The Core Obesity Model. |
| Author(s): Sandra Lopes 1, Henrik H Meincke 1, Mark Lamotte 2, Anamaria-Vera Olivieri 3, Michael E J Lean 4
|
| Affiliations(s): 1Novo Nordisk A/S Søborg Denmark.
2IQVIA Zaventem Belgium.
3IQVIA Basel Switzerland.
4Human Nutrition School of Medicine, Dentistry and Nursing Royal Infirmary University of Glasgow Glasgow UK. |
Publication(s): Obesity Science & Practice 2021. https://doi.org/10.1002/osp4.495
|
| Document Type(s): Article, |
| Countries: Belgium, Switzerland, |
| Click here for the abstract |
C:
Y: |
Health economics, Obesity,
2021 |
|
L:
A: |
English
Clinical setting: Primary care, Cost effectiveness, |
|
|
| |
| |
| External Validation of the Core Obesity Model to Assess the Cost Effectiveness of Weight Management Interventions |
| Author(s): Sandra Lopes 1, Pierre Johansen 2, Mark Lamotte 3, Phil McEwan 4, Anamaria-Vera Olivieri 5, Volker Foos 4 |
| Affiliations(s): 1Novo Nordisk A/S, Søborg, Denmark. snlb@novonordisk.com.
2Novo Nordisk A/S, Søborg, Denmark.
3IQVIA, Zaventem, Belgium.
4Health Economics and Outcomes Research Ltd, Cardiff, UK.
5IQVIA, Basel, Switzerland. |
Publication(s): Pharmacoeconomics 2020 https://doi.org/10.1007/s40273-020-00941-3 + Pharmacoeconomics. 2021 Jan;39(1):137-138. doi: 10.1007/s40273-020-00982-8. Epub 2020 Nov 30
|
| Document Type(s): Article, |
| Countries: Belgium, Denmark, Switzerland, UK, |
| Click here for the abstract |
C:
Y: |
Health economics, Obesity,
2020 |
|
L:
A: |
English
Clinical setting: Primary care, Cost effectiveness, |
|
|
| |
| |
| Real-World Clinical Effectiveness of Liraglutide 3.0 mg
for Weight Management in Canada |
| Author(s): Sean Wharton1, Aiden Liu2, Arash Pakseresht2, Emil N?rtoft3, Christiane L. Haase3, Johanna Mancini4, G. Sarah Power5, Sarah Vanderlelie1, and Rebecca A. G. Christensen1 |
| Affiliations(s): 1 Wharton Medical Clinic, Burlington, Canada. Correspondence: Sean Wharton (wharton@whartonmedicalclinic.com) 2 Novo Nordisk Canada Inc., Mississauga,
Canada 3 Novo Nordisk A/S, S?borg, Denmark 4 IQVIA, Kirkland, Canada 5 IQVIA, Mississauga, Canada. |
Publication(s): Obesity (Silver Spring). 2019 Jun;27(6):917-924. doi: 10.1002/oby.22462. Epub 2019 May 7.
|
| Document Type(s): Article, |
| Countries: Canada, Nordic, |
| Click here for the abstract |
C:
Y: |
Obesity,
2019 |
|
L:
A: |
English
|
|
|
| |
| |
| Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada |
| Author(s): 1. Sean Wharton
Wharton Medical Clinic,
Burlington, ON, Canada
2. Aiden R Liu
Novo Nordisk Canada,
Mississauga, ON, Canada
3. Arash Pakseresht
Novo Nordisk Canada,
Mississauga, ON, Canada
4. Emil Nørtoft
Novo Nordisk A/S,
Copenhagen, Denmark
5. Christiane L Haase
Novo Nordisk A/S,
Copenhagen, Denmark
6. Johanna Mancini
IQVIA, Montreal, QC,
Canada
7. G Sarah Power
IQVIA, Mississauga, ON,
Canada
8. Sarah VanderLelie
Wharton Medical Clinic,
Burlington, ON, Canada
9. Rebecca AG Christensen
Wharton Medical Clinic,
Burlington, ON, Canada |
| Affiliations(s): 1. Sean Wharton
Wharton Medical Clinic,
Burlington, ON, Canada
2. Aiden R Liu
Novo Nordisk Canada,
Mississauga, ON, Canada
3. Arash Pakseresht
Novo Nordisk Canada,
Mississauga, ON, Canada
4. Emil Nørtoft
Novo Nordisk A/S,
Copenhagen, Denmark
5. Christiane L Haase
Novo Nordisk A/S,
Copenhagen, Denmark
6. Johanna Mancini
IQVIA, Montreal, QC,
Canada
7. G Sarah Power
IQVIA, Mississauga, ON,
Canada
8. Sarah VanderLelie
Wharton Medical Clinic,
Burlington, ON, Canada
9. Rebecca AG Christensen
Wharton Medical Clinic,
Burlington, ON, Canada |
Publication(s): ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD, USA
|
| Document Type(s): Poster, |
| Countries: Canada, |
| Click here for the abstract |
C:
Y: |
Obesity,
2018 |
|
L:
A: |
English
Retrospective cohort analysis, |
|
|
| |
| |
| Excess Healthcare Resource Utilization in Obesity Pharmacotherapy Candidates in Canada |
| Author(s): Feroz T1, Charland K2, Heembrock S2, Borrelli R2, Skovgaard R1 |
| Affiliations(s): 1 NovoNordisk Canada Inc. Canada 2 IMS Brogan Canada |
Publication(s): 13th International Conference on Obesity, 2016, May 1-4, Vancouver, Canada
|
| Document Type(s): Poster, |
| Countries: Canada, |
| Click here for the abstract |
C:
Y: |
Drug Utlization Study, Obesity,
2016 |
|
L:
A: |
English
Retrospective cohort analysis, |
|
|
| |
| |
| Body mass index and all-cause mortality in patients with hypertension |
| Author(s): Xu W, Shubina M, Goldberg SI & Turchin A |
| Affiliations(s): Harvard Medical School, Boston
|
Publication(s): Obesity (Silver Spring)
23(8):1712-20
|
| Document Type(s): Article, |
| Countries: UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Obesity,
2015 |
|
L:
A: |
English
Retrospective database analysis, |
|
|
| |
| |
| Effect of adjustable gastric banding on quality of life and weight loss in the Helping Evaluate Reduction in Obesity (HERO) registry study: 2-year analysis |
| Author(s): Lao W-L, Malone DC, Armstrong EP, Voellinger D, Somers S, Jin J, Dreyer N, Globe D |
| Affiliations(s): |
Publication(s): Current Medical Research & Opinion 2015: Posted on-line July 8, 2015. doi: 10.1185/03007995.2015.1059802
|
| Document Type(s): Article, |
| Countries: |
C:
Y: |
Obesity,
2015 |
|
L:
A: |
English
RWLPR (Real-World Late Phase Research-quintiles, |
|
|
| |
| |
| Prevalence of Comorbidities and Baseline Characteristics of LAP-BAND AP® Subjects in the Helping Evaluate Reduction in Obesity (HERO) Study |
| Author(s): Dreyer NA, Dixon JB, Okerson T, Finkelstein EA, Globe D |
| Affiliations(s): |
| Publication(s): |
| Document Type(s): Article, |
| Countries: |
C:
Y: |
Obesity,
2013 |
|
L:
A: |
English
RWLPR (Real-World Late Phase Research-quintiles, |
|
|
| |
| |
| Safety Assessment of an Anti-Obesity drug (Sibutramine) |
| Author(s): Tyczynski JE1,Oleske DM2, Klingman D3 Ferrufino CP4, Lee WC4 |
| Affiliations(s): 1 Astellas Pharma, Northbrook, IL,USA 2 Abbott Laboratories, Abbott, IL, USA 3 Gainsville, VA, USA 4 IMS Health, Falls Church, VA, USA |
Publication(s): Drug Safety 2012;35(8):629-644
|
| Document Type(s): Article, |
| Countries: Germany, UK, |
C:
Y: |
Obesity,
2012 |
|
L:
A: |
English
Retrospective cohort analysis, |
|
|
| |
| |
 1 of 4 
|
